Literature DB >> 17670848

Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome.

H Der1, G Kerekes, K Veres, P Szodoray, J Toth, G Lakos, G Szegedi, P Soltesz.   

Abstract

Primary antiphospholipid syndrome (APS) is characterized by venous or arterial thrombotic events and/or recurrent abortions, fetal death, preeclasmpsia, eclampsia in the presence of anticardiolipin antibodies or lupus anticoagulant, in the absence of accompanying diseases. Antiphospholipid antibodies can activate endothelial cells, and were recently implicated in atherosclerosis. To assess potential endothelial impairment and early signs of atherosclerosis, flow-mediated (endothelium-dependent) and nitrate-mediated (endothelium independent) vasodilation, as well as von Willebrand factor antigen level and carotid artery intima-media thickness (IMT) were measured in patients with primary antiphospholipid syndrome and in healthy controls. Flow-mediated vasodilation in patients with primary APS was significantly lower than that of controls (3.43 +/- 2.86% versus 7.96 +/- 3.57%; P < 0.0001). We also found significantly higher von Willebrand antigen levels in patients with primary APS than in the control group (157.91 +/- 52.45% versus 125.87 +/- 32.8%; P = 0.012). Moreover, carotid artery IMT was significantly larger in the primary APS group compared to controls (0.714 +/- 0.2 mm versus 0.58 +/- 0.085 mm; P = 0.0037). Our results reflect ongoing endothelial damage and accelerated atherosclerosis in patients with primary APS, and suggest that vasoprotective therapy may be beneficial in the treatment of these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17670848     DOI: 10.1177/0961203307080224

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  16 in total

1.  Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome.

Authors:  Robert C Grenn; Srilakshmi Yalavarthi; Alex A Gandhi; Nayef M Kazzaz; Carlos Núñez-Álvarez; Diego Hernández-Ramírez; Antonio R Cabral; W Joseph McCune; Paula L Bockenstedt; Jason S Knight
Journal:  Ann Rheum Dis       Date:  2016-07-18       Impact factor: 19.103

2.  Antiphospholipid antibodies attenuate endothelial repair and promote neointima formation in mice.

Authors:  Victoria Ulrich; Eddy S Konaniah; Wan-Ru Lee; Sadiksha Khadka; Yu-Min Shen; Joachim Herz; Jane E Salmon; David Y Hui; Philip W Shaul; Chieko Mineo
Journal:  J Am Heart Assoc       Date:  2014-10-14       Impact factor: 5.501

Review 3.  Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?

Authors:  Salma Siddique; Jessie Risse; Guillaume Canaud; Stéphane Zuily
Journal:  Curr Rheumatol Rep       Date:  2017-09-04       Impact factor: 4.592

Review 4.  Mechanism of arterial remodeling in chronic allograft vasculopathy.

Authors:  Qichang Zheng; Shanglong Liu; Zifang Song
Journal:  Front Med       Date:  2011-10-02       Impact factor: 4.592

Review 5.  Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome.

Authors:  Roberta Gualtierotti; Martina Biggioggero; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

6.  Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients.

Authors:  Natasa Stanisavljevic; L Stojanovich; D Marisavljevic; A Djokovic; V Dopsaj; J Kotur-Stevuljevic; J Martinovic; L Memon; S Radovanovic; B Todic; D Lisulov
Journal:  Clin Rheumatol       Date:  2016-08-25       Impact factor: 2.980

Review 7.  Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome.

Authors:  Paul R J Ames; Annamaria Margarita; Jose Delgado Alves
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

8.  Does the presence of secondary antiphospholipid syndrome in patients with systemic lupus erythematodes accelerate carotid arteries intima-media thickness changes?

Authors:  Aleksandra Djokovic; Lj Stojanovich; N Stanisavljevic; V Bisenic; S Radovanovic; I Soldatovic; D V Simic
Journal:  Rheumatol Int       Date:  2013-11-15       Impact factor: 2.631

9.  A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases.

Authors:  Pál Soltész; Henriett Dér; György Kerekes; Péter Szodoray; Gabriella Szücs; Katalin Dankó; Yehuda Shoenfeld; Gyula Szegedi; Zoltán Szekanecz
Journal:  Clin Rheumatol       Date:  2009-02-18       Impact factor: 2.980

Review 10.  Management of cardiovascular disease risk in chronic inflammatory disorders.

Authors:  Mariana J Kaplan
Journal:  Nat Rev Rheumatol       Date:  2009-04       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.